Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Actemra (Tocilizumab) Market From 2025 To 2029?

In recent years, the market size for actemra (tocilizumab) has experienced a significant expansion. The forecast indicates that it will increase from $5,160 million in 2024 to $5,710 million in 2025, yielding a compound annual growth rate (CAGR) of 10.7%. Factors contributing to the growth during the historical period include a rise in autoimmune diseases, wider acceptance of biologic therapies, heightened awareness of chronic inflammation conditions, robust regulatory approvals in primary markets, and enhanced healthcare infrastructure in developed areas.

What Is the Projected Market Size of the Actemra (Tocilizumab) Market?

The market for actemra (tocilizumab) is set to experience notable growth in the coming years, with an anticipated value of $8,480 million in 2029 and a compound annual growth rate of 10.4%. This growth during the forecasted period can be tied to several factors: the widening of therapeutic applications, including COVID-19 cytokine release syndrome, the increasing preference for personalised medicine, development and acceptance of biosimilars, the rise in healthcare spending in burgeoning markets, and a growing knowledge of biologic therapies in developing regions. Key trends expected throughout the forecast period consist of a rising adoption of subcutaneous formulations, heightened concentration on biosimilar development to cut costs, advancements in biotechnology for superior drug delivery systems, continuous clinical trials for fresh therapeutic indications, and strategic collaborations and investments within the pharmaceutical sector.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19849&type=smp

Who are the Major Competitors in the Actemra (Tocilizumab) Market Outlook?

Major companies operating in the actemra (tocilizumab) market include Roche Holding AG, Fresenius Kabi

What Is Fueling Growth in the Actemra (Tocilizumab) Market?

As the occurrence of rheumatoid arthritis increases, it’s anticipated that the actemra (tocilizumab) market will see corresponding growth. This chronic autoimmune disorder, which causes joint inflammation, damage and resulting in a lower quality of life, is prevalent in millions of individuals worldwide. Smoking, obesity, environmental factors, and hormones are among the main influencing factors in this disease’s development. Actemra (tocilizumab) effectively minimizes inflammation and joint damage caused by rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor, particularly for patients who don’t respond to alternative treatments. For example, in April 2024, the National Institute for Health and Care Research (NIHR), a UK government agency, reported that approximately 700,000 UK residents live with rheumatoid arthritis. Further, in June 2024, the Australian Institute of Health and Welfare stated that approximately 514,000 Australians, or 2.0% of the population, were diagnosed with rheumatoid arthritis in 2022. In 2023, this disease represented 2.0% of total disease cases and 16% of musculoskeletal disorder cases. In addition, in 2022, rheumatoid arthritis was associated with 1,322 deaths, translating to a rate of 5.1 deaths per 100,000 individuals and accounting for 0.7% of all deaths. Such figures underline the growing prevalence of rheumatoid arthritis, inevitably fuelling the actemra (tocilizumab) market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=19849&type=smp

Which Actemra (Tocilizumab) Market Segments Are Growing the Fastest?

The actemra (tocilizumab)market covered in this report is segmented –

1) By Product Type: Min Purity Less Than 98%; Min Purity 98%-99%; Min Purity More Than 99%

2) By Dosage: Injection; Solution; Concentrate

3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

5) By Application: Cytokine Release Syndrome (CRS); Systemic Juvenile Idiopathic Arthritis (sJIA); Giant Cell Arteritis (GCA); Rheumatoid Arthritis (RA)

Which Industry Trends Are Shaping the Future of the Actemra (Tocilizumab) Market?

In the actemra (tocilizumab) market, the main trend is concentrated on the development of innovative solutions such as tocilizumab biosimilar, as a strategy to maintain competitive dominance in the industry. Tocilizumab biosimilars have gained approval for treating autoimmune diseases and COVID-19, providing a substitute for the originator drug, Actemra. For example, Fresenius Kabi, a health care company based in Germany, in November 2023, introduced Tyenne, the primary tocilizumab biosimilar referencing RoActemra (tocilizumab) in the European Union. Tyenne is sanctioned for treating a broad range of inflammatory and immune diseases, including but not limited to rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, cytokine release syndrome (CRS), and COVID-19.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/actemra-tocilizumab-global-market-report

Which Countries Are Leading the Actemra (Tocilizumab) Market?

North America was the largest region in the actemra (Tocilizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actemra (tocilizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19849

This Report Delivers Insight On:

1. How big is the actemra (tocilizumab) market, and how is it changing globally?

2. Who are the major companies in the actemra (tocilizumab) market, and how are they performing?

3. What are the key opportunities and risks in the actemra (tocilizumab) market right now?

4. Which products or customer segments are growing the most in the actemra (tocilizumab) market?

5. What factors are helping or slowing down the growth of the actemra (tocilizumab) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model